高血压患者血管紧张素转换酶抑制剂、血管紧张素Ⅱ受体拮抗剂相关基因突变率差异的单臂Meta分析OA

Objective To analyze the difference of gene mutation rates of angiotensin-converting enzyme inhibitors(ACEI)and angiotensin Ⅱ receptor blockers(ARB)in hypertensive population.Methods A total of 177 hypertensive patients in Lintong Re-habilitation&Convalescence Center from November 2022 to November 2024 were selected for ACEI and ARB gene testing.Rstudio packages were used to compare the results with 25 similar studies involving 11,221 patients with hypertension identified through litera-ture search and screening for statistical analysis such as heterogeneity testing and combined effect size.Results The combined 26 stud-ies showed heterogeneity in the mutation rates of ACE(I/D),CYP2C9(∗1/∗3),and AGTR1(1166A>C)genes.The mutation rates of the three gene loci after the combined effect size were 35.93%(95%CI:33.48%-38.47%),4.32%(95%CI:3.85%-4.85%),and 6.45%(95%CI:5.85%-7.10%),respectively.Conclusions The mutation rates of CYP2C9(∗1/∗3)and AGTR1(1166A>C)genes in Chinese hypertensive population are relatively low,and the sensitivity of metabolic enzymes and targets sites in most hypertensive patients is normal,so it is reasonable to take conventional doses of ACEI and ARB drugs.